Prostate Cancer: Correlation of MR Imaging and MR Spectroscopy with Pathologic Findings After Radiation Therapy-initial Experience

Overview

Journal Radiology

Specialty Radiology

Date 2005 Jun 24

PMID 15972335

Citations 55

Authors

Darko Pucar

Amita Shukla-Dave

Hedvig Hricak

Chaya S Moskowitz

Kentaro Kuroiwa

Semra Olgac

Lanie E Ebora

Peter T Scardino

Jason A Koutcher

Kristen L Zakian

Affiliations

Soon will be listed here.

Abstract

Purpose: To prospectively evaluate magnetic resonance (MR) imaging and MR spectroscopy for depiction of local prostate cancer recurrence after external-beam radiation therapy, with step-section pathologic findings as the standard of reference.

Materials And Methods: Study received institutional approval, and written informed consent was obtained. Study was compliant with Health Insurance Portability and Accountability Act. Sextant biopsy, digital rectal examination, MR imaging, MR spectroscopy, and salvage radical prostatectomy with step-section pathologic examination were performed in nine patients with increasing prostate-specific antigen levels after external-beam radiation therapy. MR imaging criterion for tumor was a focal nodular region of reduced signal intensity at T2-weighted imaging. MR spectroscopic criteria for tumor were voxels with choline (Cho) plus creatine (Cr) to citrate (Cit) ratio ([Cho + Cr]/Cit) of at least 0.5 or voxels with detectable Cho and no Cit in the peripheral zone. Sensitivity and specificity of sextant biopsy, digital rectal examination, MR imaging, and MR spectroscopy were determined by using a prostate sextant as the unit of analysis. For feature analysis, MR imaging and MR spectroscopic findings were correlated with step-section pathologic findings.

Results: MR imaging and MR spectroscopy showed estimated sensitivities of 68% and 77%, respectively, while sensitivities of biopsy and digital rectal examination were 48% and 16%, respectively. MR spectroscopy appears to be less specific (78%) than the other three tests, each of which had a specificity higher than 90%. MR spectroscopic feature analysis showed that a metabolically altered benign gland could be falsely identified as tumor by using MR spectroscopic criteria; further analysis of MR spectroscopic features did not lead to improved MR spectroscopic criteria for recurrent tumor.

Conclusion: In summary, MR imaging and MR spectroscopy may be more sensitive than sextant biopsy and digital rectal examination for sextant localization of cancer recurrence after external-beam radiation therapy.

Citing Articles

Detection and staging of radio-recurrent prostate cancer using multiparametric MRI.

Kowa J, Soneji N, Sohaib S, Mayer E, Hazell S, Butterfield N Br J Radiol. 2021; 94(1120):20201423.

PMID: 33586998 PMC: 8010529. DOI: 10.1259/bjr.20201423.

Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer.

Chesnut G, Tin A, Sivaraman A, Takeda T, Lee T, Fainberg J Urol Oncol. 2021; 39(8):495.e17-495.e24.

PMID: 33583697 PMC: 8542418. DOI: 10.1016/j.urolonc.2021.01.011.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

Kishan A, Chu F, King C, Seiferheld W, Spratt D, Tran P Eur Urol. 2019; 77(2):201-208.

PMID: 31718822 PMC: 7008470. DOI: 10.1016/j.eururo.2019.10.008.

Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1.

Granlund K, Tee S, Vargas H, Lyashchenko S, Reznik E, Fine S Cell Metab. 2019; 31(1):105-114.e3.

PMID: 31564440 PMC: 6949382. DOI: 10.1016/j.cmet.2019.08.024.

Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT).

Alexander E, Murray J, Morgan V, Giles S, Riches S, Hazell S Radiother Oncol. 2019; 141:181-187.

PMID: 31493904 PMC: 6908966. DOI: 10.1016/j.radonc.2019.07.030.

References

Rogers E, Ohori M, Kassabian V, Wheeler T, Scardino P . Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995; 153(1):104-10. DOI: 10.1097/00005392-199501000-00037. View

Lerner S, Blute M, Zincke H . Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol. 1995; 154(3):1103-9. View

Kurhanewicz J, Vigneron D, Hricak H, Narayan P, Carroll P, Nelson S . Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996; 198(3):795-805. DOI: 10.1148/radiology.198.3.8628874. View

Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron D, Nelson S . Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology. 1996; 48(4):594-9. DOI: 10.1016/S0090-4295(96)00250-6. View

Costello L, Franklin R . Citrate metabolism of normal and malignant prostate epithelial cells. Urology. 1997; 50(1):3-12. DOI: 10.1016/S0090-4295(97)00124-6. View

Engelbrecht M, Huisman H, Laheij R, Jager G, van Leenders G, Hulsbergen-van de Kaa C . Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 2003; 229(1):248-54. DOI: 10.1148/radiol.2291020200. View

Cheng L, Cheville J, Bostwick D . Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol. 1999; 23(10):1173-83. DOI: 10.1097/00000478-199910000-00002. View

Gheiler E, Tefilli M, Tiguert R, Grignon D, Cher M, Sakr W . Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998; 51(5):789-95. DOI: 10.1016/s0090-4295(98)00096-x. View

Star-Lack J, Nelson S, Kurhanewicz J, Huang L, Vigneron D . Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med. 1997; 38(2):311-21. DOI: 10.1002/mrm.1910380222. View

10.

Mettlin C, Murphy G, McDonald C, Menck H . The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999; 86(9):1877-82. View

11.

Scheidler J, Hricak H, Vigneron D, Yu K, Sokolov D, Huang L . Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology. 1999; 213(2):473-80. DOI: 10.1148/radiology.213.2.r99nv23473. View

12.

Yu K, Scheidler J, Hricak H, Vigneron D, Zaloudek C, Males R . Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999; 213(2):481-8. DOI: 10.1148/radiology.213.2.r99nv26481. View

13.

Males R, Vigneron D, Star-Lack J, Falbo S, Nelson S, Hricak H . Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med. 2000; 43(1):17-22. DOI: 10.1002/(sici)1522-2594(200001)43:1<17::aid-mrm3>3.0.co;2-6. View

14.

Podo F . Tumour phospholipid metabolism. NMR Biomed. 2000; 12(7):413-39. DOI: 10.1002/(sici)1099-1492(199911)12:7<413::aid-nbm587>3.0.co;2-u. View

15.

Kurhanewicz J, Vigneron D, Males R, Swanson M, Yu K, Hricak H . The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am. 2000; 38(1):115-38, viii-ix. DOI: 10.1016/s0033-8389(05)70152-4. View

16.

Nudell D, Wefer A, Hricak H, Carroll P . Imaging for recurrent prostate cancer. Radiol Clin North Am. 2000; 38(1):213-29. DOI: 10.1016/s0033-8389(05)70157-3. View

17.

van der Graaf M, Schipper R, Oosterhof G, Schalken J, Verhofstad A, Heerschap A . Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA. 2000; 10(3):153-9. DOI: 10.1007/BF02590640. View

18.

Wefer A, Hricak H, Vigneron D, Coakley F, Lu Y, Wefer J . Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000; 164(2):400-4. View

19.

Obuchowski N, Lieber M, Powell K . Data analysis for detection and localization of multiple abnormalities with application to mammography. Acad Radiol. 2000; 7(7):516-25. DOI: 10.1016/s1076-6332(00)80324-4. View

20.

Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M . Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000; 48(2):355-67. DOI: 10.1016/s0360-3016(00)00637-4. View